Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:09 AM
Ignite Modification Date:
2025-12-25 @ 2:09 AM
NCT ID:
NCT00006760
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed refractory or relapsed Hodgkin's lymphoma
* Mixed cellularity, not otherwise specified (NOS)
* Lymphocytic depletion, NOS
* Lymphocytic depletion, diffuse fibrosis
* Lymphocytic depletion, reticular
* Lymphocytic predominance, NOS
* Lymphocytic predominance, diffuse
* Lymphocytic predominance, nodular
* Hodgkin's paragranuloma NOS
* Hodgkin's granuloma
* Hodgkin's sarcoma
* Nodular sclerosis, NOS
* Nodular sclerosis, cellular phase
* Nodular sclerosis, lymphocytic predominance
* Nodular sclerosis, mixed cellularity
* Nodular sclerosis, lymphocytic depletion
* Other (type not specified)
* In first relapse
* Metastasis to bone marrow with granulocytopenia, anemia, and/or thrombocytopenia allowed
* Not enrolled on POG-9426 unless there is an extranodal site of recurrence
PATIENT CHARACTERISTICS:
Age:
* Under 30 at diagnosis
Performance status:
* Lansky 60-100% (for patients 16 years and under)
* Karnofsky 60-100% (for patients over 16 years)
Life expectancy:
* At least 2 months
Hematopoietic:
* See Disease Characteristics
* Absolute neutrophil count at least 1,000/mm\^3
* Platelet count at least 75,000/mm\^3 (transfusion independent)
Hepatic:
* Bilirubin no greater than 1.5 times normal
* SGOT or SGPT less than 2.5 times normal
Renal:
* Creatinine no greater than 1.5 times normal
* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
Cardiovascular:
* Shortening fraction at least 27% by echocardiogram OR
* Ejection fraction at least 50% by gated radionuclide
Other:
* No other concurrent serious illness
* No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or any other component of study drugs
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* No concurrent immunomodulating agents
Chemotherapy:
* At least 2 weeks since prior chemotherapy (3 weeks for nitrosoureas) and recovered
* No other concurrent anticancer chemotherapy
Endocrine therapy:
* No concurrent steroids
* No concurrent corticosteroids (e.g., dexamethasone)
Radiotherapy:
* Recovered from prior radiotherapy
Surgery:
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
30 Years
Study:
NCT00006760
Study Brief:
Protocol Section:
NCT00006760